Log in to search using one of your social media accounts:

 

FDA Approves Landmark Cancer Therapy; Wilmot Positioned Among First to Offer It

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news

Related Links:

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells, Published online: 23 November 2017; doi:10.1038/s41408-017-0005-zNR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Authors: Duan H, Wang R, Yan X, Liu H, Zhang Y, Mu D, Han J, Li X Abstract 2,4,6-trihydroxy-3-(4-hydroxyphenyl)-propiophenone (phloretin) is found in apple tree leaves and the Manchurian apricot, and is a potent compound that exhibits anti-inflammatory, antioxidant and antitumor activities. However, the effect of phloretin on esophageal cancer cells is not well-defined. The present study aimed to examine whether and how phloretin induced apoptosis in human esophageal cancer cells. EC-109 cells were cultured in Dulbecco's modified Eagle's medium and incubated with 60, 70, 80, 90 and 100 µg/ml phloretin for 6, ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Sargın Yıldırım N, Demirkaya M, Sevinir BB, Güler S, Vural AP, Demiröz C, Çırpan Kantarcıoğlu A Abstract Background/aim: The aim of this study was the determination and prospective follow-up of quality of life, depression, and anxiety in pediatric patients with cancer under chemotherapy, as well as the evaluation of related factors. Materials and methods: Fifty newly diagnosed pediatric cancer patients and their parents were prospectively monitored before, during, and after therapy, and tests were used. Results: Significantly lower quality of life scores were recorded during treatme...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Authors: Cho H, Kim SH, Kim SJ, Chang JH, Yang WI, Suh CO, Kim YR, Jang JE, Cheong JW, Min YH, Kim JS Abstract Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In this article, learn about the types of bone marrow cancer, including multiple myeloma, leukemia, and lymphomas. How are they diagnosed and treated?
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
In Reply We read with interest the letter by Manson et al. They describe another case of hair repigmentation (HR) in a male patient with concomitant advanced colorectal cancer and Hodgkin lymphoma treated with nivolumab and showing a good response. Interestingly, this new case seems to support the association between a good response and HR.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
Authors: Hayashi N, Fujita A, Saikai T, Takabatake H, Sotoshiro M, Sekine K, Kawana A Abstract Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large-cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the affordability of cancer treatments at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. Th... Author: VJHemOnc Added: 11/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
(UNC Lineberger Comprehensive Cancer Center) A grant from The Leukemia&Lymphoma Society will help fund clinical research led by UNC Lineberger's Barbara Savoldo, MD, PhD, into an investigational chimeric antigen receptor (CAR) T-cell treatment for acute lymphoblastic leukemia that would include a built-in 'safety switch.'
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Mantle cell lymphoma (MCL) is a group of aggressive B-cell lymphomas displaying heterogeneous outcomes after treatment. Some patients have the slowly progressing disease that does not require immediate treatment, while others have a disease that rapidly progresses despite highly aggressive treatment. A number of prognostic tools have been described to determine whether patients have slow or rapidly progressing diseases, including the mantle cell lymphoma International Prognostic Index (MIPI) and biomarkers, such as KI-67.Researchers have discovered a novel method of predicting a MCL patient ’s overall survival progno...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Lymphoma | Universities & Medical Training